CAS: 77-36-1; Chlorthalidone

该化合物是一种类似硫酸的二尿素,通常用于治疗高血压和与心脏衰竭,肝硬化和肾病有关的水肿,其特点是能够抑制钠重新吸附于的溶解管管管,导致钠和水的排泄增加,有助于降低血压和减少液积.氯二烯的半衰期很长,允许一次日服,而且往往偏好于其持续的抗合性效应.该化合物通常以口服形式施用,并因其在管理高血压方面的效力而著称,通常与其他抗合剂结合使用.除其主要用途外,氯二烯还可能对钙的代谢性作用产生有益影响,有时还被用于防止肾结石.其化学结构包括一种氨基化合物,有助于其亚尿性能.任何药物中的潜在副作用包括电解不平衡,特别是低血压治疗期间的病人非常重要.

结构式图片

欧盟法规

ECHA物质ECHA物质化妆品禁用物质清单C&L通报REACH预注册

上下游产品

(-)-Chlortalidon chloroform 2-chloro-5-(1-chloro-3-oxo-phthalan-1-yl)-benzenesulfonyl chloride ammonia2-(4-chloro-3-sulfamoyl-benzoyl)-benzoic acid Chlortalidon-methylether (+)-Chlortalidon (-)-Chlortalidon

合成工艺路线路线简述

    4-(4-Chlorophenyl)-1H-2,3-Benzoxazin-1-One置于氯磺酸,Ammonium Hydroxide,双氧水,溶剂黄146,Sodium Hydroxide,锌体系中,用 水,丙酮 作为反应溶剂,化学反应 2.0H,反应生成 氯噻酮
    参考文献: Improved Process For The Preparation Of Chlorthalidone[fr] Procédé Amélioré Pour La Préparation De Chlorthalidone
    标题: Improved Process For The Preparation Of Chlorthalidone[fr] Procédé Amélioré Pour La Préparation De Chlorthalidone
    摘要:本发明涉及制备氯噻酮的方法.具体来说,所披露的工艺在工业规模上是可行的,并且提供了基本纯净的氯噻酮.

    海关参考信息

    专利信息


    专利号:US-10925977-B2
    优先权日:2006-10-05
    标 题 :Efficient synthesis of chelators for nuclear imaging and radiotherapy: compositions and applications
    发明人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S
    权利人:YANG DAVID J; YU DONGFANG; THOMPSON ANDREW S; CEIL POINT LLC; UNIV TEXAS
    摘要:Novel methods of synthesis of chelator-targeting ligand conjugates, compositions comprising such conjugates, and therapeutic and diagnostic applications of such conjugates are disclosed. The compositions include chelator-targeting ligand conjugates optionally chelated to one or more metal ions. Methods of synthesizing these compositions in high purity are also presented. Also disclosed are methods of imaging, treating and diagnosing disease in a subject using these novel compositions, such as methods of imaging a tumor within a subject and methods of diagnosing myocardial ischemia.

    专利号:US-10973847-B2
    优先权日:2017-06-30
    标题 :Core-to-surface polymerization for the synthesis of star polymers and uses thereof
    发明人:JOHNSON JEREMIAH A; GOLDER MATTHEW R
    权利人:MASSACHUSETTS INST TECHNOLOGY
    摘要:Disclosed are methods, compositions, reagents, systems, and kits to prepare star polymers, as well as compositions and uses thereof. Various embodiments show that synthesis of these polymers contain low metal concentration to provide polymers for diverse biomedical applications including in vivo applications.

    专利号:US-10005720-B2
    优先权日:2013-04-05
    标题:Compounds useful for the treatment of metabolic disorders and synthesis of the same
    发明人:SEXTON JONATHAN Z; BRENMAN JAY E; MUSSO DAVID L
    权利人:NORTH CAROLINA CENTRAL UNIV; UNIV NORTH CAROLINA CHAPEL HILL
    摘要:The present invention provides compounds of Formula (I): wherein variables X, Y, Z and R1 are as described herein. Some of the compounds described herein are glutamate dehydrogenase activators. The invention is also directed to pharmaceutical compositions comprising these compounds, uses of these compounds and compositions in the treatment of metabolic disorders as well as synthesis of the compounds.

    专利号:US-2008287407-A1
    优先权日:2003-12-10
    标题 :Nitric Oxide Releasing Pyruvate Compounds, Compositions and Methods of Use
    发明人:GARVEY DAVID S; FANG XINQIN; KHANAPURE SUBHASH P; RANATUNGA RAMANI R; WEY SHIOW-JYI
    权利人:NITROMED INC
    摘要:The invention describes novel nitrosated and/or nitrosylated pyruvate compounds and pharmaceutically acceptable salts thereof, and novel compositions comprising at least one nitrosated and/or nitrosylated pyruvate compound, and, optionally, at least one compound that donates, transfers or releases nitric oxide, stimulates endogenous synthesis of nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor or is a substrate for nitric oxide synthase, and/or at least one therapeutic agent. The invention also provides novel compositions comprising at least one pyruvate compound and at least one compound that donates, transfers or releases nitric oxide, elevates endogenous levels of endothelium-derived relaxing factor, stimulates endogenous synthesis of nitric oxide or is a substrate for nitric oxide synthase and/or at least one therapeutic agent. The invention also provides novel kits comprising at least one pyruvate compound, that is optionally nitrosated and/or nitrosylated, and, optionally, at least one nitric oxide donor and/or at least one therapeutic agent. The invention also provides methods for treating diseases resulting from oxidative stress, diabetes, reperfusion injury following ischemia, preservation of tissues, organs, organ parts and/or limbs.

    专利号:US-2024368164-A1
    优先权日:2021-04-28
    标 题 :Purine nucleosides, their intermediates, and methods of preparation thereof
    发明人:RAVI RAMA SURESH; JACOBSON KENNETH A; POE RUSSELL BIRCH
    权利人:ASTROCYLE PHARMACEUTICALS INC; US HEALTH
    摘要:The present invention provides purine nucleoside analog compounds and methods of use thereof for treatment of certain injuries, disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries. The present invention further provides methods of synthesizing such compounds, and intermediates useful in the synthesis of such compounds.

    专利号:US-2008090885-A1
    优先权日:2006-10-12
    标题:Preparation of losartan 5-carboxylic acid and use thereof
    发明人:CHEN LIQIN; LI JIAN; SHEN YINGZHONG
    权利人:CHEN LIQIN; LI JIAN; SHEN YINGZHONG
    摘要:A method for synthesis of losartan 5-carboxylic acid (EXP-3174).
    成都宇洋高科技发展有限责任公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.yygk.com
    电话: 0086-28-61777709👤
    📞成都宇洋高科技发展有限责任公司 ⚠️参考联系方式

    销售电话:0086-28-61777709
    邮箱:yygk@yygk.com
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别 ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Tsai MC, Wu J, Kupfer S, Vakilynejad M. Population Pharmacokinetics and Exposure-Response of a Fixed-Dose Combination of Azilsartan Medoxomil and Chlorthalidone in Patients with Stage 2 Hypertension. J Clin Pharmacol. 2015 Dec 3. doi: 10.1002/jcph.684. [Epub ahead of print] doi: 10.1007/s11845-015-1350-1. Epub 2015 Sep 4. doi: 10.3949/ccjm.82a.14091. Review. doi: 10.1016/j.jchromb.2015.03.018. Epub 2015 Mar 28. doi: 10.1161/HYPERTENSIONAHA.114.05021. Epub 2015 Mar 2. Review. doi: 10.5681/apb.2015.019. Epub 2015 Mar 5.
    8: Kipnes MS, Handley A, Lloyd E, Barger B, Roberts A. Safety, tolerability, and efficacy of azilsartan medoxomil with or without chlorthalidone during and after 8 months of treatment for hypertension. J Clin Hypertens (Greenwich). 2015 Mar;17(3):183-92. doi: 10.1111/jch.12474. Epub 2015 Jan 24. doi: 10.1007/s13181-014-0419-y.
    10: Roush GC, Ernst ME, Kostis JB, Kaur R, Sica DA. Not just chlorthalidone: evidence-based, single tablet, diuretic alternatives to hydrochlorothiazide for hypertension. Curr Hypertens Rep. 2015 Apr;17(4):540. doi: 10.1007/s11906-015-0540-6. doi: 10.2217/fca.14.83. Review. doi: 10.1097/IJG.0000000000000037. doi: 10.1111/jch.12453. Epub 2014 Dec 15. doi: 10.1111/jch.12413. Epub 2014 Sep 25. doi: 10.1124/jpet.114.215566. Epub 2014 Sep 4.

    合成参考文献


    参考文献:10.4061/2011/417594
    摘要:Demede M, Pandey A, Innasimuthu L, Jean-Louis G, McFarlane SI, Ogedegbe G. Management of Hypertension in High-Risk Ethnic Minority with Heart Failure. International Journal of Hypertension. 2011;2011():1–8. doi: 10.4061/2011/417594.
    参考文献:10.4061/2011/495349
    摘要:Katholi RE, Couri DM. Left Ventricular Hypertrophy: Major Risk Factor in Patients with Hypertension: Update and Practical Clinical Applications. International Journal of Hypertension. 2011;2011():1–10. doi: 10.4061/2011/495349.
    参考文献:10.2174/1874192401105010085
    摘要:Tziomalos K, Athyros VG, Karagiannis A, Mikhailidis DP. Dyslipidemia induced by drugs used for the prevention and treatment of vascular diseases. Open Cardiovasc Med J. 2011;5():85–9.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知